Association of hypertension with symptoms of benign prostatic hyperplasia

Journal of Urology

Volumn 172, Issue 4 I, 2004, Pages 1390-1393

  Michel, Martin C ^a,e   Heemann, Uwe ^b   Schumacher, Helmut ^c   Mehlburger, Ludwig ^c   Goepel, Mark ^d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c B Ingelheim Pharma GmbH/Co KG   (Germany)

^d Klinikum Niederberg   (Germany)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Aging; Epidemiology; Hypertension; Prostatic hyperplasia

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

AGED; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; HUMAN; HYPERTENSION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RETROSPECTIVE STUDY; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYMPATHETIC TONE;

EID: 4544319602     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000139995.85780.d8     Document Type: Article

References (19)

1. Boyle, P. and Napalkov, P.: The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol Suppl, 168: 7, 1995
2. Bourke, J. B. and Griffm, J. P.: Hypertension, diabetes mellitus, and blood groups in benign prostatic hypertrophy. Br J Urol, 38: 18, 1966
3. Morrison, A. S.: Prostatic hypertrophy in greater Boston. J Chronic Dis, 31: 357, 1978
4. Sidney, S., Quesenberry, C., Jr., Sadler, M. C., Lydick, E. G., Guess, H. A. and Cattolica, E. V.: Risk factors for surgically treated benign prostatic hyperplasia in a prepaid health care plan. Urology, suppl., 38: 13, 1991
5. Glynn, R. J., Campion, E. W., Bouchard, G. R. and Silbert, J. E.: The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol, 121: 78, 1985
6. Michel, M. C., Mehlburger, L., Bressel, H.-U., Schumacher, H., Schafers, R. F. and Goepel, M.: Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does comorbidity alter tolerability? J Urol, 160: 784, 1998
7. Kornitzer, M., Dramaix, M. and De Backer, G.: Epidemiology of risk factors for hypertension: implications for prevention and therapy. Drugs, 57: 695, 1999
8. Steers, W. D., Clemow, D. B., Persson, K., Sherer, T. B., Andersson, K. E. and Tuttle, J. B.: The spontaneously hypertensive rat: insight into the pathogenesis of irritative symptoms in benign prostatic hyperplasia and young anxious males. Exp Physiol, 84: 137, 1999
9. Spitsbergen, J. M., Clemow, D. B., McCarty, R., Steers, W. D. and Tuttle, J. B.: Neurally mediated hyperactive voiding in spontaneously hypertensive rats. Brain Res, 790: 151, 1998
10. Goldstein, D. S.: Plasma catecholamines and essential hypertension. An analytical review. Hypertension, 5: 86, 1983
11. Michel, M. C., Brodde, O. E. and Insel, P. A.: Peripheral adrenergic receptors in hypertension. Hypertension, 16: 107, 1990
12. Michel, M. C., Schafers, R. F. and Goepel, M.: Alpha-blockers and lower urinary tract function: more than smooth muscle relaxation? BJU Int, suppl., 86: 23, 2000
13. Tong, Y. C., Hung, Y. C., Lin, S. N. and Cheng, J. T.: The norepinephrine tissue concentration and neuropeptide Y immunoreactivity in genitourinary organs of the spontaneously hypertensive rat. J Auton Nerv System, 56: 215, 1996
14. Platz, E. A., Kawachi, I., Rimm, E. B., Colditz, G. A., Stampfer, M. J., Willett, W. C. et al: Physical activity and benign prostatic hyperplasia. Arch Intern Med, 158: 2349, 1998
15. Small, K. M., McGraw, D. W. and Liggett, S. B.: Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol, 43: 381, 2003
16. Lepor, H., Williford, W. O., Barry, M. J., Brawer, M. K., Dixon, C. M., Gormley, G. et al: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med, 335: 533, 1996
17. Debruyne, F. M., Jardin, A., Colloi, D., Resel, L., Witjes, W. P., Delauche-Cavallier, M. C. et al: Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. Eur Urol, 34: 169, 1998
18. Kirby, R. S., Roehrborn, C., Boyle, P., Bartsch, G., Jardin, A., Cary, M. M. et al: Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology, 61: 119, 2003
19. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA, 283: 1967, 2000